PREVENTABLE (PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr adults) is a 20,000-subject randomized trial funded by the National Institute of Aging that will examine the overall benefits and risks of cholesterol-lowering drugs known as statins in adults age 75 or older without cardiovascular disease. The trial will help determine whether a statin can help prevent dementia and disability in this age group, as well as heart attacks and other cardiovascular-related deaths, while not increasing risks of adverse health outcomes.
Wake Forest School of Medicine houses two components of PREVENTABLE. The data coordinating center is housed within PHS and the Geriatric Assessment Center is housed in Geriatrics. WFSM is partnering with Duke University, which will house the Clinical Coordinating Center; the Boston V; the VA Cooperative Studies Pharmacy; and PCORnet to conduct this study.
PREVENTABLE Study Team including PHS team members: PI, Walter Ambrosius, PhD, Nicholas Pajewski, PhD, David Reboussin, PhD, Janet Davis and Letitia Perdue
National Estimates of the Impact of the Affordable Care Act on Healthcare Utilization, Outcomes & Quality Among Hispanics
The Affordable Care Act (ACA) insurance coverage expansions beginning in 2014 resulted in historic reductions in the rate of uninsured adults in the states that expanded Medicaid and in the other states. An estimated 26.7 million gained either Medicaid or subsidized private insurance by 2017. A major ongoing research study of the newly established Program in Health Services Research examines the impact of ACA on racial/ethnic disparities on access to healthcare and patient outcomes.
As part of the NIMHD-funded study, we have assembled a large database of the near-universe of individual discharge and ED records of all patients (all ages, race/ethnicities and payers) from all hospitals in 22 states from 2010 to 2017. In collaboration with researchers at Boston University School of Medicine, our agenda is to study the utilization of a wide range of inpatient and ED services – preventable hospitalizations and ED visits, cardiac procedures, knee replacement, bariatric surgery, heart transplant, LVAD use, safety-net hospital use, inpatient deaths – to add to the evidence base on ACA's longer term impact on access to healthcare, with a particular focus on Hispanics and other racial/ethnic minorities. Given their comprehensive coverage of all inpatient care, these data are suitable for studying a broad range of topics: adoption of new therapies, rare diseases and treatments, geographic variations, proximity to providers, costs, and risk prediction. We welcome new collaborators in extending the use of this rich resource!
Study Team: Amresh Hanchate Director; Meng-Yun Lin Faculty; Maria Parries Program Manager; Danyang Qi Data Analyst; Zhixiu Liu Data Analyst
Evaluating the Impact of Waterpipe Tobacco Marketing Claims on Young Adults
In 2019, the NCI and FDA Center for Tobacco Products funded Erin Sutfin, PhD, and her team’s R01 Evaluating the Impact of Waterpipe Tobacco Marketing Claims on Young Adults. Waterpipe tobacco (WT) smoking is common among young adults in the U.S. Despite significant health effects associated with waterpipe tobacco smoking, young adults erroneously believe WT smoking is less harmful and less addictive than cigarette smoking. Marketing, including package design and digital marketing (websites and social media), is an effective tool used by the tobacco industry to communicate product health information to consumers. The common use of fruit imagery and text describing the quality of the tobacco may be associated with reduced harm perceptions.
The FDA has begun to prohibit certain claims on WT packaging and in marketing. Some prohibited claims are easily identifiable, but others are more difficult to identify due to lack of specificity in the law and the implicit nature of some claims. Evidence is needed, specific to WT packaging and marketing, to identify claims and determine their influence on consumer harm misperceptions to inform future regulatory actions. This study will address this gap by documenting claims on WT packaging and in digital marketing and identifying how such claims influence consumer perceptions. The findings will help the FDA determine which claims consumers interpret in ways that the law prohibits, which could prompt the FDA to engage in additional rulemaking so consumers are not misled.
Study Team: Erin Sutfin, PhD; Jennifer Ross, PhD; Kimberly Wagoner, DrPH, MPH; Beth Reboussin, PhD; Caroline Kimes, BS; Bobby Amoroso, BS; Cindy Suerken, MS; Eric Soule, PhD, Eastern Carolina University; Alison Lazard, PhD, University of North Carolina; Desmond Jenson, JD, Public Health Law Center
The SEARCH for Diabetes in Youth (SEARCH) study was initiated in 2000 and has been funded for 20 years with funding to address major knowledge gaps in the understanding of childhood diabetes. Wake Forest serves as the data coordinating center for the SEARCH study providing scientific support for protocol development, statistical analysis and data management. The CDC provides funding for the SEARCH Registry Study, which is a study of the incidence and prevalence of type 1 diabetes and type 2 diabetes in youth occurring over the past two decades in five geographically distinct locations of the U.S. and represents the largest, most diverse study of diabetes among U.S. youth.
We observed that the incidence of both type 1 and type 2 diabetes increased significantly over this period, particularly among youths of minority racial and ethnic groups. The NIDDK provides funding for the SEARCH Cohort Study, which has followed, longitudinally, a cohort of children since their diagnosis with either type 1 or type 2 diabetes. These children are now young adults and they are at the stage of life where they are developing complications of diabetes. We measured diabetic kidney disease, retinopathy, peripheral neuropathy, cardiovascular autonomic neuropathy, arterial stiffness and hypertension in more than 2,000 youth with diabetes.
Study Team: Ralph D’Agostino, Jr, PhD, Lynne Wagenknecht, DrPH, Elizabeth Jensen, PhD, Jasmin Divers, PhD, Andrew South, MD, Beth Reboussin, PhD, Brian Wells, PhD, Ramon Casanova, PhD, Leora Henkin, Carrie Williams, Maureen Goldstein, Jennette Stafford, Scott Isom, Cindy Seurken, Kristin Lenoir, Jerry Barnes, Ken Wilson, John Hepler, June Pierce, Julia Spell, Danielle Cunio, Rhonda Blaine, James Lovato
NCI Community Oncology Research Program (NCORP)
The NCI Community Oncology Research Program (NCORP) was launched in 2014 to ensure that people can participate in clinical trials focused on cancer control, prevention and care delivery, regardless of where they live. The Wake Forest NCORP Research Base is one of seven research bases funded by the NCI to develop and implement cancer prevention and control research for the NCORP community oncology research network. We partner with NCORP Community and Minority Underserved Community Sites across the country to test new approaches to cancer care delivery and the treatment, prevention and detection of cancer-related symptoms. Our goal is to conduct practice-changing cancer research that will improve patient outcomes. Our studies are designed to be easy to implement and manage. Almost without exception, we will provide drugs for the study at no cost to the patient and limit any follow up to that which is relevant to the study.
For the second time in five years, the Wake Forest NCORP has been recognized by the NCI and has been granted a six-year $25 million award that will build on the previous work done through an $18 million award received in 2014. The grant is designed to focus on extending ongoing clinical research in cardiovascular and neurocognitive complications of cancer treatments and on improving patient well-being during cancer care.
Led by Glenn Lesser, MD, and Kathryn Weaver, PhD. WFSM study team: Karen Craver, Ruth Wright, Renee Glenn, Jenna Gerosa, Bill Stanfield, Eden Gurganus, Cissy Yates, Rhonda Kimball, Dell Campbell, Scarlett Hutchens, Tanny Vogler, Julie Turner, June Fletcher-Steede
Action for Health in Diabetes (Look AHEAD) Study
The Action for Health in Diabetes (Look AHEAD) Study is a randomized trial of 5,145 participants comparing the effects of Intensive Lifestyle Intervention (ILI) focused on weight loss achieved through healthy eating and increased physical activity versus a control condition of Diabetes Support and Education (DSE) in overweight and obese individuals with type 2 diabetes. The intervention phase of the trial ended in 2012 at which time it was determined that the intervention had no effect on the primary outcome of heart disease. We are now in the 20th year of the study, which is referred to as the Look AHEAD Extension (LA-E). The goal of LA-E is to examine whether ILI, provided for 10 years during mid-life, has enduring benefits that persist beyond the period of the intervention for older individuals with diabetes.
LA-E focuses on the clinical outcomes most relevant to healthy aging and resilience and will provide the long-term data needed to frame guidelines related to lifestyle intervention in the care of older overweight or obese individuals with type 2 diabetes. Outcomes in LA-E include mortality, health care costs, frailty, microvascular complications of diabetes (eye, kidney and nerve) and quality of life.
Wake Forest Division of Public Health Sciences serves as the data coordinating center. An important strength of the study is our spirit of collaboration. Within our institution, collaborating departments over the years have included cardiology, neurology, geriatrics, and health adn exercise science on the Reynolda Campus.
Led by Mark Espeland and Lynne Wagenknecht, the WFSM study team includes: Andrea Anderson, Judy Bahnson, Michael Bancks, Jerry Barnes, Mary Barr, Patricia Beatty, Tara Beckner, Peter Brubaker, Haiying Chen, Delilah Cook, Katelyn Garcia, Sarah Gaussoin, Kate Hayden, Lea Harvin, Denise Houston, Rebecca Neiberg, Nick Pajewski, June Pierce, David Reboussin, Jack Rejeski, Debbie Steinberg, Michael Walkup, Christopher Webb, and Carrie Williams.
Microbiome and Insulin Longitudinal Evaluation Study (MILES) is a collaboration between Cedars-Sinai (Mark Goodarzi, project PI) and Wake Forest School of Medicine (Alain Bertoni field center PI and Elizabeth Jensen Co-I), LABiomed, Baylor College of Medicine and University of Virginia. This 30-month observational study is investigating the relationship between organisms that live in the gastro-intestinal (GI) track and glucose metabolism. The study has just finished up the recruitment stage. Enrollment has exceeded the expected target of 300 Non-Hispanic white and African American men and women between the ages of 40-85. There are thought to be links between the foods one eats, the gut and microorganisms that live there, levels of the hormone insulin, and glucose, the main sugar that provides energy for the body to function. Data will be collected at 3 time points on non-diabetic participants over three years to better understand why some people develop type 2 diabetes.
The aims are as follows:
- Specific Aim 1: Characterize the change in the insulin axis (insulin sensitivity, secretion, clearance) and characterize metabolic homeostasis in two race/ethnic groups (White and African American) by performing an oral glucose challenge at three clinic visits over 30 months.
- Specific Aim 2: Determine the gut microbiota composition at each visit, specifically organisms that produce short chain fatty acids (SCFA). We will estimate the effect of the gut microbiota (our primary predictor) on the insulin axis (insulin sensitivity, insulin secretion, and insulin clearance), alone and jointly with habitual diet, in two race/ethnic groups.
- Specific Aim 3: Establish microbial functions that determine changes over time in the insulin axis in the context of the gut microbiota, habitual diet, and circulating SCFA levels (as an effect modifier).
Led by Principal Investigator Alain Bertoni and co-investigator, Elizabeth Jensen, the Wake Forest team includes: Lenore Crago, Mary Kelsey Trumps, Rosalia Arnolda, Katlyn Hodges, Joey Curran.
We all know sleep is important. But how does sleep actually affect our overall health as we age? And what if there was a simple tool we could use to identify a potential invention to avoid negative health outcomes? Unfortunately, for postmenopausal women in particular, these questions go unanswered. Laura Baker, PhD (Gerontology & Geriatric Medicine and Social Sciences & Health Policy) and her team in Public Health Sciences are tackling these questions with the WHISPER (Women’s Health Initiative Sleep hyPoxia Effects on Resilience) Study.
WHISPER examines the role of nocturnal intermittent hypoxia and other adverse sleep exposures on cardiovascular events and progression, cancer incidence and severity and cognitive trajectory, including risk of mild cognitive impairment (MCI), Alzheimer’s disease (AD) and related dementias in older women from the Women’s Health Initiative Extension Study cohort. Dr. Baker’s team serves as the study’s coordinating center, in collaboration with Harvard University, California Pacific Medical Center, Stanford University, the Fred Hutchinson Cancer Research Center and the University of North Carolina-Chapel Hill. Funding is from the NIH/NHLBI.
WHISPER is currently in the process of enrolling 5,000 postmenopausal women across the U.S. to complete a one-time sleep assessment using two at-home, low cost, wristworn devices: the Itamar WatchPAT (to measure oximetry for one night) and the ActiLife Actigraph (to measure actigraphy for four days and four nights). Both devices have been validated to provide reliable estimates of sleep-disordered breathing (WatchPAT) and sleep duration/variation (Actigraph)—which have been identified as risk factors for negative health outcomes.
A unique aspect of WHISPER is that participants do not report to a clinic site to receive and be trained in the use of the sleep assessment devices. Instead, devices are mailed to the participants from the WHISPER offices in 525@vine and devices are returned by mail where the sleep data are downloaded for analysis. Enrolled participants receive a shipment including pictorial instruction cards, a self-report sleep diary, and the two wrist worn sleep devices. Participants receive phone calls throughout the sleep assessment to discuss the instructions and to be interviewed.
The results of this study have the potential to impact routine clinical care by providing an alternative cost-efficient, low burden, home-based sleep assessment for patients at highest risk for cardiovascular disease, cancer, and cognitive impairment.
Led by Principal Investigator Dr. Laura Baker, the WFSM study team includes: Dan Beavers, Steve Rapp, David Reboussin, Sally Shumaker, Bev Snively, Bonnie Sachs, Alyssa Anderson, Mark Brown, Lynn Callahan, Danielle Cunio, Heather Dailey, Jonna Daniel, Brittany Davis, Sharnita Duren, Ann Furstenburg, Leslie Gordineer, Darrin Harris, Leonard Jordan, Deb Kampman, Margaret Pearce, Debbie Pleasants, Julia Robertson, Margaret Scales, Cheryl Summerville.